Skystar Bio-Pharmaceutical Co (FRA:GNJC) Liabilities-to-Assets : 0.29 (As of Sep. 2014)

Skystar Bio-Pharmaceutical Co Liabilities-to-Assets Chart

Skystar Bio-Pharmaceutical Co Annual Data
	Trend	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13
Liabilities-to-Assets		Get a 7-Day Free Trial					0.11	0.12	0.15	0.17	0.19

Skystar Bio-Pharmaceutical Co Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Liabilities-to-Assets	Get a 7-Day Free Trial															0.22	0.19	0.18	0.28	0.29

Competitive Comparison of Skystar Bio-Pharmaceutical Co's Liabilities-to-Assets

For the Drug Manufacturers - General subindustry, Skystar Bio-Pharmaceutical Co's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Skystar Bio-Pharmaceutical Co's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Skystar Bio-Pharmaceutical Co's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Skystar Bio-Pharmaceutical Co's Liabilities-to-Assets falls into.

Skystar Bio-Pharmaceutical Co Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Skystar Bio-Pharmaceutical Co's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2013 is calculated as:

Skystar Bio-Pharmaceutical Co's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2014 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skystar Bio-Pharmaceutical Co  (FRA:GNJC) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Skystar Bio-Pharmaceutical Co Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Skystar Bio-Pharmaceutical Co's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Skystar Bio-Pharmaceutical Co (FRA:GNJC) Business Description